Program
SI-B036
A development code.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Head and Neck Neoplasms · Breast Neoplasms · Digestive System Neoplasms · Urologic Neoplasms, led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 77 open or running | phase 1since May 19, 2026 | May 19, 2026 | Oct 2028phase 1 · NCT07857616 |
Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2026First study: phase 1 study in Solid TumorFirst studyNCT07606612 · 31 planned · China
- Jun 25, 2026Phase 1 study in Digestive System NeoplasmsNCT07678970 · 10 planned · China
- Jul 30, 2026Phase 1 study in Urologic NeoplasmsNCT07744243 · 30 planned · China
- Aug 4, 20263 phase 1 studiesNCT07753226, NCT07763639, NCT07778862
- Sep 22, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07857616 · 424 planned · United States
Ahead
- Oct 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07857616
- Dec 2028Primary completion: phase 1 study in Gynecological TumorsNCT07778862
- Dec 2028Primary completion: phase 1 study in Head and Neck NeoplasmsNCT07763639
- Dec 2028Primary completion: phase 1 study in Breast NeoplasmsNCT07753226
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07857616Carcinoma, Non-Small-Cell Lung · United States | 1 | Recruiting | Oct 2028 | 424 |
| NCT07778862Gynecological Tumors · China | 1 | Not yet recruiting | Dec 2028 | 30 |
| NCT07763639Head and Neck Neoplasms · China | 1 | Recruiting | Dec 2028 | 30 |
| NCT07753226Breast Neoplasms · China | 1 | Recruiting | Dec 2028 | 39 |
| NCT07744243Urologic Neoplasms · China | 1 | Not yet recruiting | Dec 2028 | 30 |
| NCT07678970Digestive System Neoplasms · China | 1 | Recruiting | Dec 2028 | 10 |
| NCT07606612Solid Tumor · China | 1 | Recruiting | Dec 2028 | 31 |
How it is read
Names in the registry
- “SI-B036”, 7 entries
Codes read as this program: SIB036.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Head and Neck Neoplasms, 1 study
- Breast Neoplasms, 1 study
- Digestive System Neoplasms, 1 study
- Urologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.